Project Grant R56DE034980
Award Date 8/7/26
Completion Date 8/6/28
Dollars Obligated $379K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- The National Institute of Child Health and Human Development awarded Beth Israel Deaconess Medical Center $724,852 on September 1, 2026, under CFDA 93.865 (Child Health and Human Development Extramural Research) to investigate lymphatic pathology caused by dysregulated NFATC1 signaling using Down syndrome as a model. The research will examine how increased dosage of chromosome 21 genes DYRK1A and DSCR1 drives NFATC1 hyperphosphorylation and functional suppression, disrupting lymphatic...
- The National Institutes of Health Office of the Director awarded University of California Irvine $6.132 million on August 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the neurobiological basis for cognitive dysfunction and dementia in aging adults with Down syndrome. The project uses spatial multi-omics techniques—combining transcriptomics, epigenomics, and proteomics—to analyze over 100 clinically characterized brain samples from individuals with Down...
- The National Institutes of Health Office of the Director awarded the University of New Mexico Health Sciences Center $419,375 on July 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate mechanisms of vascular dysfunction in Down syndrome. The research examines endothelial dysfunction and glycocalyx depletion in a mouse model of Down syndrome (TCMAC21 mice) to understand cardiovascular disease risk in the Down syndrome population. The study investigates how...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded $845,935 to the Research Institute At Nationwide Children's Hospital on July 21, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to establish a single-cell and spatial atlas of trisomy 21 hearts using both Down syndrome mouse models and patient-specific induced pluripotent stem cells. The award funds research aimed at elucidating cellular and tissue mechanisms of septal...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded the University of Wisconsin System $568,615 on September 2, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the molecular mechanisms underlying synaptic deficiency in Down syndrome. The research project, titled "Molecular Mechanisms Underlying Synaptic Deficiency in Down Syndrome" (R01HD120347), will use isogenic trisomy 21 disorder-specific human...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- The National Institute of Child Health and Human Development awarded the University of Connecticut Health Center $457,875 on September 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and deploy an inducible gene dosage correction system in Down syndrome organoid and rodent models carrying human chromosome 21. The research uses an XIST-based transgene system to reversibly silence one copy of chromosome 21 across multiple cell types,...
- The National Institute of Allergy and Infectious Diseases awarded Benaroya Research Institute At Virginia Mason $496,344 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the DYRK1A-GP130 axis drives immune dysregulation in Down syndrome and other autoimmune conditions. The research dissects molecular mechanisms by which DYRK1A, a kinase encoded on chromosome 21, regulates differentiation of pro-autoimmunity TH17 cells and...
- The National Institute of Neurological Disorders and Stroke awarded the University of Virginia $490,593 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of growth differentiation factor 11 (GDF11) in neurodevelopmental disorders. The research examines GDF11 as a molecular hub involved in abnormal brain function across multiple genetically distinct neurodevelopmental disorders. The first...